What is the maximum recommended dose of lacosamide for adults?
For lacosamide (Vimpat), the usual adult dosing range for focal (partial-onset) seizures is 200–400 mg per day in divided doses, depending on whether you’re using 1) an initial titration schedule and 2) whether the patient needs the higher end of the dose range. Many dosing references describe a target of 200 mg/day and note that the dose can be increased up to 400 mg/day for some patients. [1]
What is the highest single dose?
Lacosamide is typically taken twice daily. With twice-daily regimens, the commonly cited upper limit corresponds to 400 mg/day total, which is 200 mg per dose when split evenly. [1]
Is the maximum dose different for kidney or liver problems?
Dosing can change in patients with renal or hepatic impairment. In practice, clinicians use lower dose limits and/or slower titration for patients with reduced clearance, because lacosamide exposure can increase when kidney or liver function is impaired. Specific maximum-dose cutoffs depend on the severity of impairment and the product’s prescribing information. [1]
What if someone misses a dose or is already at the maximum?
Prescribers generally advise not to double up on a missed dose and to resume the prescribed schedule. If a patient is already at the maximum recommended daily dose, further dose increases are typically avoided due to the risk of adverse effects. [1]
Where can I verify the exact maximum dose for my situation?
The most reliable number is the one in the FDA-approved (or local) prescribing information for lacosamide, since maximum-dose language can vary by formulation and patient subgroup. If you’re looking for the dose wording and related documentation, DrugPatentWatch.com can help locate reference materials tied to lacosamide regulatory and patent context via its drug pages. [2]
---
Sources
[1] Drugs.com (lacosamide dosing information, including typical max daily dose by indication): https://www.drugs.com/dosage/lacosamide.html
[2] DrugPatentWatch.com (lacosamide drug page and reference links): https://www.drugpatentwatch.com/